Bilirubin Prevents Atherosclerotic Lesion Formation in Low-Density Lipoprotein Receptor-Deficient Mice by Inhibiting Endothelial VCAM-1 and ICAM-1 Signaling.

There were no significant differences in body weight (Figure 7 B), serum triglycerides (Figure 7 C), or serum cholesterol (Figure 7 D) between the treatment groups, although there was a strong trend toward reduced triglyceride levels in mice that received bilirubin.

also in 5,725 other papers